185329-76-4

Basic information

• Product Name: 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97%
• Synonyms: 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97%;4-Bromo-2-thiophenesulfonyl chloride;4-broMothiophene-2-sulfonyl chloride
• CAS NO: 185329-76-4
• Molecular Formula: C₄H₂BrClO₂S₂
• Molecular Weight: 261.54448
• Mol File: 185329-76-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 110.4℃
• Boiling Point: 322.157 °C at 760 mmHg
• Flash Point: 148.636 °C
• Appearance: /
• Density: 1.985 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97%(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97%(185329-76-4)
• EPA Substance Registry System: 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97%(185329-76-4)

Safety Data

• Hazard Codes: C:Corrosive
• Statements: R34:Causes burns.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36/37/39:Wear suitabl
• Hazardous Substances Data: 185329-76-4(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-thiophenesulfonyl chloride, also known as 4-Bromothiophenesulfonyl chloride, is a chemical compound with a purity of 97%. It is a yellow to brown liquid with a strong, acrid odor. 4-BROMO-2-THIOPHENESULFONYL CHLORIDE,97% is an important building block in organic synthesis, particularly in the pharmaceutical industry for the production of various pharmaceutical intermediates. It is also used in the synthesis of fluorescent dyes and biologically active molecules. 4-Bromo-2-thiophenesulfonyl chloride is a versatile and valuable reagent with a wide range of applications in chemical research and industrial processes.

Upstream product

• 872-31-1 3-Bromothiophene 
• 3140-92-9 2,4-dibromothiophene 

Downstream Products

• 210691-56-8 4-Bromo-thiophene-2-sulfonic acid [2-(3-{[((E)-6,6-dimethyl-hept-2-en-4-ynyl)-ethyl-amino]-methyl}-phenoxy)-ethyl]-methyl-amide 

Relevant articles and documents

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]X-A-Y-Z-L-R1??(I)[/in-line-formulae] which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.